Fig. 7: Gilteritinib effectively inhibits tumor growth in the HDST model ex vivo.
From: Antitumor activity of gilteritinib, an inhibitor of AXL, in human solid tumors
A HDST analysis was used to assess the therapeutic effect of gilteritinib on different PDX derived explants (PDXE). The PDXE fragments submerged with hydrogel to form an ex vivo culture system. B The expression of AXL was analyzed by immunohistochemistry in the PDEXs from human GC samples (GC-616 and GC488), OCs (OC-1351 and OC-973), and EC samples (EC-1239 and EC-1236). The images were captured at 200× magnification (left) and 400× magnification (right). Scale bars: 50 µm (left) and 20 µm (right). C Cells from the indicated PDXE were treated with 100 mM gilteritinib and 83 mM CDDP (Cisplatin) as a positive control for 5 days, before detecting the cell viability by CCK-8. Data are presented as the mean ± standard error of the mean (SEM); the statistical significance was determined by unpaired t-test (**p < 0.01; ***p < 0.001).
